ISPOR UAE Chapter and AbbVie announce intent to collaborate on healthcare advancement
The ISPOR UAE Chapter, the local chapter of the leading international scientific and educational organization for health economics and outcomes research (HEOR), and AbbVie, a global biopharmaceutical company, have announced their intent to explore collaborative opportunities aimed at enhancing healthcare outcomes in the UAE. The Letter of Intent (LOI) was signed during the Abu Dhabi Global Health Week in the presence of senior board members from the ISPOR UAE Chapter and senior leadership from AbbVie Gulf.
The LOI signifies a mutual commitment to work together in key areas including Health Technology Assessment (HTA) and policy shaping, as well as research and evidence generation. This collaboration aims to leverage the ISPOR UAE Chapter's extensive network and knowledge in HEOR and AbbVie's scientific expertise to contribute to a more robust and evidence-based healthcare system in the UAE.
Prof. Nadia Al Mazrouei, ISPOR UAE Chapter President, emphasised that 'The ISPOR UAE Chapter is dedicated to fostering excellence in health economics and outcomes research to inform healthcare decisions in the UAE. This Letter of Intent with AbbVie, formalized during the prestigious Abu Dhabi Global Health Week, marks an important step in bridging our network of researchers, policymakers, and healthcare professionals with industry expertise. We are enthusiastic about the potential of this collaboration to generate impactful research and contribute to the development of evidence-based policies that benefit patients across the UAE.'
Elhussein Abdellatif, General Manager Gulf Levant AbbVie, stated, 'We are proud to reaffirm our commitment to elevating the standards of care and enhancing patients' lives. We understand the vital importance of Health Technology Assessment (HTA) and health policy in supporting access to essential therapies. Our collaboration with the ISPOR UAE Chapter provides us with an opportunity to share our expertise and collectively advance toward a more sustainable and patient-focused healthcare ecosystem in the UAE.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
15-05-2025
- Zawya
Saudi Arabia hosts landmark Ophthalmology Meeting to advance (DME) and (RVO) Treatment
Under the title 'Holistic pro-Inflammatory Target for Sight (HITS)' the Ophthalmology Pivotal Meeting kicked off in Saudi Arabia on April 25, 2025, under the auspices of AbbVie, the global biopharmaceutical research and development company. This is a significant move to elevate the standard of care for various eye conditions like Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO). More than 100 national and international ophthalmologists participated in the meeting, which included scientific lectures and in-depth workshops to leverage applied medical specialties in ophthalmology and optics, exchange knowledge and expertise, and help change perspectives on the best ways to improve patient outcomes. It also discussed treatment and management methods of these prevalent diseases. In his lecture, Dr. Mattias Iglicki, Consultant Ophthalmologist, Vitreoretinal Surgeon and Researcher from University of Buenos Aires, Argentina, praised the convening of this meeting, which is a good opportunity to discuss the latest advancements and clinical trials in the presence of this elite group of international retinal specialists, along with local experts. He explained that diabetic macular edema, which is often the result of high blood sugar levels in diabetics, accompanied with leaky blood vessels leading to swelling in the retina. On the other hand, retinal vein occlusion occurs when the retinal veins are blocked, causing fluid buildup and impaired vision. Both conditions are serious and require proactive management to prevent the disease from worsening. Dr. Iglicki emphasized that organizing such medical summits and conferences serves as a platform for sharing and disseminating the cutting-edge research and developments in treating eye diseases, especially DME and RVO, which are diseases whose rates are increasing with the increasing incidence of diabetes. This enables the attending ophthalmologists to implement these updates in their practices, which in turn advances treatment methods in the Kingdom of Saudi Arabia in accordance with the latest international recommendations and technologies, thus improving the lives of patients and alleviating their daily suffering. For his part, Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, pointed out that Saudi Arabia's hosting of such medical meetings and seminars reflects the Kingdom's interest in promoting medical education and exchanging scientific expertise between international and local physicians to highlight the most important scientific and medical developments and provide distinguished medical care. By organizing this congress, AbbVie underscores its commitment to enhancing patient outcomes through educational initiatives and collaboration among eye care professionals. Sharing knowledge and expertise at such events is crucial to our ongoing efforts to refine treatment strategies, improve patients' quality of life, and help make a real difference in their lives. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.
Zawya
15-05-2025
- Zawya
Saudi Arabia hosts landmark ophthalmology meeting to advance DME and RVO treatment
Under the title 'Holistic pro-Inflammatory Target for Sight (HITS)' the Ophthalmology Pivotal Meeting kicked off in Saudi Arabia on April 25, 2025, under the auspices of AbbVie, the global biopharmaceutical research and development company. This is a significant move to elevate the standard of care for various eye conditions like Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO). More than 100 national and international ophthalmologists participated in the meeting, which included scientific lectures and in-depth workshops to leverage applied medical specialties in ophthalmology and optics, exchange knowledge and expertise, and help change perspectives on the best ways to improve patient outcomes. It also discussed treatment and management methods of these prevalent diseases. In his lecture, Dr. Mattias Iglicki, Consultant Ophthalmologist, Vitreoretinal Surgeon and Researcher from University of Buenos Aires, Argentina, praised the convening of this meeting, which is a good opportunity to discuss the latest advancements and clinical trials in the presence of this elite group of international retinal specialists, along with local experts. He explained that diabetic macular edema, which is often the result of high blood sugar levels in diabetics, accompanied with leaky blood vessels leading to swelling in the retina. On the other hand, retinal vein occlusion occurs when the retinal veins are blocked, causing fluid buildup and impaired vision. Both conditions are serious and require proactive management to prevent the disease from worsening. Dr. Iglicki emphasized that organizing such medical summits and conferences serves as a platform for sharing and disseminating the cutting-edge research and developments in treating eye diseases, especially DME and RVO, which are diseases whose rates are increasing with the increasing incidence of diabetes. This enables the attending ophthalmologists to implement these updates in their practices, which in turn advances treatment methods in the Kingdom of Saudi Arabia in accordance with the latest international recommendations and technologies, thus improving the lives of patients and alleviating their daily suffering. For his part, Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, pointed out that Saudi Arabia's hosting of such medical meetings and seminars reflects the Kingdom's interest in promoting medical education and exchanging scientific expertise between international and local physicians to highlight the most important scientific and medical developments and provide distinguished medical care. By organizing this congress, AbbVie underscores its commitment to enhancing patient outcomes through educational initiatives and collaboration among eye care professionals. Sharing knowledge and expertise at such events is crucial to our ongoing efforts to refine treatment strategies, improve patients' quality of life, and help make a real difference in their lives. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Zawya
07-05-2025
- Zawya
MOU between the Saudi Society of Dermatology and Dermatologic Surgery (SSDDS), AbbVie and Al Nahdi Medical Company
Saudi Arabia: The Saudi Society of Dermatology and Dermatologic Surgery SSDDS, the leading professional body for dermatologists in Saudi Arabia, signed a Memorandum of Understanding with AbbVie Saudi Arabia, the global biopharmaceutical research and development company, and Al Nahdi Medical Company, the largest retail pharmacy chain in the Middle East and Africa. The MOU aims to collaborate on enhancing public health services, awareness programs, and advancing disease management through innovative healthcare solutions. The MOU also aims to strengthen the role of the Saudi Society of Dermatology through partnerships between the private and public entities to drive innovative healthcare solutions in line with Saudi Vision 2030. Dr. Abdullah Al-Aqeel, President of SSDDS, pointed out that the MOU primarily aims to collaborate on patient education and awareness campaigns, particularly on psoriasis and atopic dermatitis, their symptoms, and treatment options. It also aims to provide patients with access to accurate and culturally relevant educational materials. It also aims to train and support healthcare professionals by conducting training sessions and workshops in collaboration with SSDDS to hone the skills of dermatologists and healthcare providers on the latest developments in the treatment of atopic dermatitis and psoriasis. Dr. Maysa Ashmawy, Head of Dermatology at Saudi Ministry of Health, and a member of the Board of the Saudi Society of Dermatology and Dermatologic Surgery, emphasized the importance of such partnerships, which aim to improve healthcare services, and to contribute to research in collaboration with SSDDS, in addition to sharing insights with healthcare providers in line with national public health objectives. Dr. Afaf Al-Sheikh, Consultant and Head of the Dermatology Department at King Abdulaziz Medical City and the National Guard, commended the signing of the MOU, which aims to establish a collaborative framework to advance the management of psoriasis and atopic dermatitis in Saudi Arabia. She also emphasized the need to raise awareness of these cases, promote early diagnosis and treatment, and improve healthcare access and quality, in alignment with Saudi Vision 2030. She added that SSDDS as always, is fulfilling its developmental and training role by organizing professional training sessions for dermatologists and healthcare providers, facilitating research initiatives, and sharing insights on disease management trends. For his part, Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, emphasized AbbVie's efforts to collaborate with health authorities in the Kingdom to provide healthcare and awareness services, provide training resources, support healthcare professional education initiatives, and collaborate on patient awareness and outreach programs. He added, AbbVie's mission is to discover and deliver innovative medicines and solutions that solve today's serious health issues and address future medical challenges. The company also strives to make a remarkable impact on people's lives in several key therapeutic areas, including immunology, oncology and neuroscience.
